Open Orphan PLC Exercise of Investor Warrants and Issue of Shares (6457Z)

TIDMORPH

RNS Number : 6457Z

Open Orphan PLC

22 September 2020

Open Orphan plc

("Open Orphan" or the "Company")

Exercise of Investor Warrants by Investor and Issue of Shares

Total Voting Rights

Open Orphan plc (ORPH), the rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models, has received a notice of exercise of warrants by an investor who participated in the Venn loan note financing in December 2018 over 269,866 ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares") at a price of 0.1 pence per share for 95,539 Ordinary Shares and at a price of 2.2 pence per share for 174,327 Ordinary Shares. The gross proceeds of this exercise received by the Company amounts to GBP3,930.74.

Following the warrant exercise, the outstanding warrants over Ordinary Shares are as follows:

 
 Number of    Exercise    Date awarded  Expiry Date           Beneficiary 
  Ordinary    Price per 
   Shares       share 
----------  -----------  -------------  ------------    ------------------------ 
  166,666     30 pence    7 June 2011   6 June 2021            An advisor 
  853,711    0.1 pence    11 December   10 December     Venn loan note investors 
                              2018          2023 
 1,557,729   2.2 pence    11 December   10 December     Venn loan note investors 
                              2018          2023 
 1,607,142   5.6 pence    28 June 2019  27 June 2024           An advisor

The Company has made application for 269,866 new Ordinary Shares, to be issued and allotted as a result of the warrant exercise set out above, to be admitted to trading on AIM and Euronext Growth. Admission is expected to occur at 8.00 a.m. on 25 September 2020.

Total Voting Rights

Following the admission of 269,866 new Ordinary Shares, the Company's total issued ordinary share capital will consist of 665,879,696 Ordinary Shares. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

For further information please contact

 
 Open Orphan plc                                  +353 (0)1 644 0007 
 Cathal Friel, Executive Chairman 
 
 Arden Partners plc (Nominated Adviser and        +44 (0)20 7614 
  Joint Broker)                                    5900 
 John Llewellyn-Lloyd / Benjamin Cryer / 
  Dan Gee-Summons 
 
                                                  +44 (0) 20 7220 
 finnCap plc (Joint Broker)                        500 
 Geoff Nash / James Thompson/ Richard Chambers 
 
 Davy (Euronext Growth Adviser and Joint 
  Broker)                                         +353 (0)1 679 6363 
 Anthony Farrell 
 
                                                  +44 (0)20 3757 
 Camarco (Financial PR)                            4980 
 Tom Huddart / Hugo Liddy

Notes to Editors - Open Orphan:

Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Conducted from Europe's only 24-bedroom quarantine clinic with onsite virology providing individually isolated rooms and connected to our specialist laboratory facility. hVIVO's challenge studies require healthy volunteers to take part, volunteers are recruited through FluCamp, learn more at www.FluCamp.com . The hVIVO facility offers highly specialised virology and immunology laboratory services to support pre-clinical and clinical respiratory drug, antiviral, and vaccine discovery and development. Reliable laboratory analysis underpinned by scientific expertise is essential when processing and analysing clinical samples. Robust quality processes support our team of scientists in the delivery of submission ready data.

The Company has a leading portfolio of 8 viral challenge study models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD viral challenge models. As announced in early March, Open Orphan is rapidly advancing a number of Coronavirus challenge study models and expects to be helping many COVID-19 vaccine development companies to test their vaccines. No other company in the world has such a portfolio, with only two competitors globally having 1 challenge study model each. hVIVO also works with companies in the UK and Ireland to provide COVID-19 testing to staff to protect staff and customers from a workplace COVID-19 outbreak through its COVID Clear offering.

Open Orphan comprises of two commercial specialist CRO services businesses, hVIVO and Venn Life Sciences and is also building out a valuable data platform business. hVIVO has built up one of the world's largest databases of infectious disease progression data and we are populating our Open Orphan Health Data platform with this historical hVIVO data. In our clinical trials going forward, we are also planning to collect data on volunteer's via wearables during clinical trials. Therefore, Open Orphan's data, which may yield valuable digital biomarkers, could be one of the more sought-after datasets by many of the large wearables /smart watch wearables providers around the world. In June 2019, Open Orphan acquired AIM-listed Venn Life Sciences Holdings plc in a reverse take-over and in January 2020 it completed the merger with hVIVO plc in January 2020. Venn is an integrated drug development consultancy firm which offers CMC (chemistry, manufacturing and controls), preclinical, Phase I & II clinical trials design and execution. The merger with hVIVO created a European full pharma services company broadening the Company's customer base and with complementary specialist CRO services, widened the range of the Company's service offerings.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFLFEDAAILFII

(END) Dow Jones Newswires

September 22, 2020 02:30 ET (06:30 GMT)

Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024